Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

April 29, 2024

Boehringer Ingelheim ‘Office Hours’ program returns to mentor 4 companies

Contributed Boehringer Ingelheim's U.S. headquarters in Ridgefield.

Boehringer Ingelheim was the 14th-largest U.S. pharmaceutical company in 2023, with revenue totaling $27.7 billion, but that doesn’t mean it won’t help the little guy.

On Wednesday, Ridgefield-based Boehringer will host another round of its Office Hours program, offering advice to entrepreneurs and emerging life-sciences businesses. The free event — held in partnership with BioCT, an organization that promotes bioscience in Connecticut —  makes senior company executives available for free to help accelerate innovation. 

According to the company website, since it was instituted in Boston in 2015, the Office Hours program has mentored over 300 early-stage companies.

This week, Boehringer will host three companies and one individual:

  • EpiTET Therapeutics, a New Haven-based startup developing novel therapeutics to tame inflammation in endometriosis and solid cancers.
  • Cloverleaf Bio, a New Haven based company developing a new class of RNA therapeutics for cancer.
  • Allagium Therapeutics, which is affiliated with Yale Ventures, is investigating new therapies for cancer, metabolic disease and rare disease, and
  • Dr. Farida Ahangari, an assistant professor in pulmonary care at Yale, who is focused on understanding the way pulmonary fibrosis originates and develops.

“Our Office Hours program offers biotech startups and entrepreneurs the opportunity to seek advice and feedback from a panel of our experts across research, business development, clinical development, medicine, marketing and beyond, depending on the company’s needs,” said Scott DeWire, Boehringer’s U.S. head of business development & licensing. “We do this in a way that’s ‘no strings attached,’ and it’s our hope that these early-stage companies will benefit from our experience and perspectives, allowing us to actively contribute to the vibrant innovation landscape in Connecticut and across the globe.”

A spokesperson for Boehringer said the program has the following guidelines:

  • Senior professionals within the company work with life-science innovators in a one-hour consultative “roundtable” setting to increase their knowledge of how to “progress their science along the value chain.”
  • There are no restrictions or conditions associated with the program. The “no-strings attached” policy encourages open dialog from both parties and has been an important contributory factor in the success of the program.
  • In advance of the meeting, participating companies are asked to submit nonconfidential background information about their technology, and up to five questions about their own programs and company, which helps tailor the program to meet the individual needs of each business.
  • Typically, questions cover a range of topics including pre-clinical and clinical development, research strategy, business development and licensing.


Sign up for Enews


Order a PDF